Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Receivables (2016 - 2026)

Cytosorbents filings provide 15 years of Receivables readings, the most recent being $14.7 million for Q4 2025.

  • On a quarterly basis, Receivables rose 13.58% to $14.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.7 million, a 13.58% increase, with the full-year FY2025 number at $14.7 million, up 13.58% from a year prior.
  • Receivables hit $14.7 million in Q4 2025 for Cytosorbents, up from $13.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $14.7 million in Q4 2025 to a low of $7.5 million in Q4 2021.
  • Median Receivables over the past 5 years was $11.0 million (2023), compared with a mean of $10.9 million.
  • The widest YoY moves for Receivables: up 53.12% in 2021, down 7.75% in 2021.
  • Cytosorbents' Receivables stood at $7.5 million in 2021, then increased by 26.09% to $9.5 million in 2022, then grew by 19.71% to $11.4 million in 2023, then increased by 13.76% to $12.9 million in 2024, then rose by 13.58% to $14.7 million in 2025.
  • The last three reported values for Receivables were $14.7 million (Q4 2025), $13.4 million (Q3 2025), and $14.4 million (Q2 2025) per Business Quant data.